{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1410001205659544576.json","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000392000990"}],"foaf:Person":[{"foaf:name":[{"@language":"en","@value":"Carfagna Mark"},{"@language":"ja","@value":"Carfagna Mark"}],"foaf:familyName":[{"@language":"en","@value":"Carfagna"},{"@language":"ja","@value":"Carfagna"}],"foaf:givenName":[{"@language":"en","@value":"Mark"},{"@language":"ja","@value":"Mark"}]}],"career":[{"institution":{"notation":[{"@language":"en","@value":"Eli Lilly & Company"},{"@language":"ja","@value":"Eli Lilly & Company"}]}}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1390001205659544576","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.14869/toxp.33.0.22.0"},{"@type":"NAID","@value":"130007004278"}],"notation":[{"@language":"en","@value":"Comparison of Nonclinical Toxicological Profiles Among PPAR Alpha, Gamma, and Delta Agonists"},{"@language":"ja","@value":"Comparison of Nonclinical Toxicological Profiles Among PPAR Alpha, Gamma, and Delta Agonists"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:1003278904_BgY9MeLBcfMTE3fgC5Owu5aEIv4"},{"@type":"CIA","@value":"130007004278_BgY9MeLBcfMTE3fgC5Owu5aEIv4"}]}